Zdravka medarova
Company: TransCode Therapeutics
Job title: cto
Seminars:
siRNA-Based Cancer Immunotherapy 12:00 pm
Unveiling TTX: a novel platform for nucleic acid delivery to tumors TTX-siPDL1 is an RNAi checkpoint inhibitor with efficacy in preclinical PDAC Demonstrating how TTX-siPDL1 activity relies on both tumor cell and TAM targetingRead more
day: Day Two